Alzinova AB (publ) (FRA:78D)

Market Cap	6.50M -70.2%
Revenue (ttm)	2.36M +50.1%
Net Income	-2.44M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	265
Open	0.0323
Previous Close	0.0367
Day's Range	0.0323 - 0.0323
52-Week Range	0.0323 - 0.2950
Beta	n/a
RSI	40.33
Earnings Date	Feb 26, 2026

About Alzinova AB

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aβ42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alzheimer’s d...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 5
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 78D

Financial Performance

In 2024, Alzinova AB's revenue was 16.81 million, a decrease of -15.41% compared to the previous year's 19.87 million. Losses were -20.55 million, 24.7% more than in 2023.

Financial numbers in SEK